Genetic variants associated with gastrointestinal symptoms in Fabry disease
暂无分享,去创建一个
Giuseppe Agapito | Pietro Hiram Guzzi | Mariamena Arbitrio | Licia Pensabene | Francesca Scionti | Maria Teresa Di Martino | P. Guzzi | Giuseppe Agapito | E. Riccio | A. Pisani | S. Sestito | M. Arbitrio | D. Concolino | F. Scionti | O. Borrelli | Daniela Concolino | Simona Sestito | Angela Nicoletti | Antonio Pisani | Eleonora Riccio | Valentina Talarico | Federica Altomare | Maria Teresa Sanseviero | Osvaldo Borrelli | V. Talarico | L. Pensabene | A. Nicoletti | M. Sanseviero | M. T. Di Martino | F. Altomare
[1] K. Köhrer,et al. Benign recurrent intrahepatic cholestasis associated with mutations of the bile salt export pump. , 2006, Journal of clinical gastroenterology.
[2] Mario Cannataro,et al. Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis , 2015, Cancer Chemotherapy and Pharmacology.
[3] Mario Cannataro,et al. OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes , 2016, Microarrays.
[4] E. Riccio,et al. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature]. , 2013, Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
[5] R. Schwartz. An atypical variant of Fabry's disease in men with left ventricular hypertrophy , 1996 .
[6] A. Kosters,et al. Bile acid transporters in health and disease , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[7] A. Tuttolomondo,et al. Neurological complications of Anderson-Fabry disease. , 2013, Current pharmaceutical design.
[8] F. Suchy,et al. Bile salt excretory pump: biology and pathobiology. , 2006, Journal of pediatric gastroenterology and nutrition.
[9] P. Dawson,et al. Bile acid transporters , 2009, Journal of Lipid Research.
[10] K. Macdermot,et al. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females , 2001, Journal of medical genetics.
[11] P. Neuvonen,et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate , 2008, Pharmacogenetics and genomics.
[12] M. Camilleri. Bile Acid Diarrhea: Prevalence, Pathogenesis, and Therapy , 2015, Gut and liver.
[13] Bradley L Urquhart,et al. Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.
[14] D. Häussinger,et al. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. , 2006, Gastroenterology.
[15] R. Kim,et al. Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.
[16] S. Feriozzi,et al. Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson–Fabry disease: testing the effects with the Mainz Severity Score Index , 2008, Clinical genetics.
[17] Richard J. Thompson,et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis , 1998, Nature Genetics.
[18] Mario Cannataro,et al. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study , 2011, Cancer biology & therapy.
[19] S. Sestito,et al. Anderson-Fabry disease in children. , 2013, Current pharmaceutical design.
[20] Mario Cannataro,et al. DMET-Analyzer: automatic analysis of Affymetrix DMET Data , 2012, BMC Bioinformatics.
[21] Mario Cannataro,et al. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine , 2016, Oncotarget.
[22] Mario Cannataro,et al. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling , 2011, British journal of haematology.
[23] C. Eng,et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. , 2003, Kidney international.
[24] A. Mehta,et al. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[25] A. Tuttolomondo,et al. Anderson-Fabry disease: a multiorgan disease. , 2013, Current pharmaceutical design.
[26] P. Meier,et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury , 2007, Pharmacogenetics and genomics.
[27] A. Staiano,et al. Subtypes of irritable bowel syndrome in children: prevalence at diagnosis and at follow-up. , 2014, The Journal of pediatrics.
[28] D. F. Moore,et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. , 2001, JAMA.
[29] Richard J. Thompson,et al. Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre‐messenger RNA splicing , 2009, Hepatology.
[30] R. Desnick. α-Galactosidase A deficiency. Fabry disease , 2001 .
[31] F. Lammert,et al. Hepatic Overexpression of Murine Abcb11 Increases Hepatobiliary Lipid Secretion and Reduces Hepatic Steatosis* , 2004, Journal of Biological Chemistry.
[32] C. Eng,et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. , 2001, The New England journal of medicine.
[33] A. Zinsmeister,et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[34] D. Keppler,et al. The Multidrug Resistance Protein 5 Functions as an ATP-dependent Export Pump for Cyclic Nucleotides* , 2000, The Journal of Biological Chemistry.
[35] S. Sestito,et al. Gastrointestinal Symptoms of Patients with Fabry Disease , 2015, Gastroenterology research and practice.
[36] R. Evers,et al. Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex , 2014, Drug Metabolism and Disposition.
[37] F. Pieruzzi,et al. Intrafamilial phenotypic variability in four families with Anderson‐Fabry disease , 2014, Clinical genetics.
[38] G. Boccia,et al. Functional defecation disorders in children: PACCT criteria versus Rome II criteria. , 2007, The Journal of pediatrics.
[39] M. Trauner,et al. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. , 2011, Biochimica et biophysica acta.
[40] M. Brys,et al. Small Fiber Dysfunction Predominates in Fabry Neuropathy , 2002, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.